Inhibition of Fosfomycin Resistance Protein FosA from Pseudomonas aeruginosa
ACS Infectious Diseases · 11.09.2026 · 12 (9) · 3043-3052
DOI: 10.1021/acsinfecdis.6c00121 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 18.08.2026. Verfasst von Vanessa Wiltsie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry & Biochemistry, The University of Alabama, 250 Hackberry Lane, Tuscaloosa, Alabama35487, United States. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Fosfomycin, Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit nennt 44 Literaturangaben. Gefördert von: NIH HHS, University of Alabama, National Institutes of Health.
Abstract (Originalsprache)
Antimicrobial resistance is an urgent issue in modern-day medicine. One way to address this problem is to repurpose and restore the function of older antibacterials through the specific targeting of antibiotic-modifying enzymes produced by bacteria. Fosfomycin is an antibiotic that is attractive for repurposing because it has been previously approved for use in uncomplicated urinary tract infections (UTIs) and is widely regarded as safe with no known off-target interactions. The primary limitation to fosfomycin usage has been the emergence of fosfomycin resistance enzymes. FosAPa is the fosfomycin resistance enzyme from Pseudomonas aeruginosa. We identified and evaluated several potential inhibitors of FosAPa using high-throughput virtual screening (HTVS) and 31P-NMR. In addition, we obtained X-ray crystal structures of FosAPa with the inhibitors bound in the active site to gain insights into important protein–ligand interactions necessary for the potential structure-based drug design. Preliminary cell-based assays were performed to evaluate the effect that the inhibitors have on the minimum inhibitory concentration (MIC) of fosfomycin in P. aeruginosa. Our results provide an initial scaffold for structure–activity relationships and future compound modifications for combating fosfomycin resistance in P. aeruginosa and other FosA-containing Gram-negative pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry & Biochemistry, The University of Alabama, 250 Hackberry Lane, Tuscaloosa, Alabama35487, United States.
- Department of Chemistry, Huntingdon College, 3104 Huntingdon College Drive, Montgomery, Alabama36106, United States.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 South Limestone St., Lexington, Kentucky40536, United States.
- Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana70803, United States.
ORCID-Profile: Nishad Thamban Chandrika, Nathaniel C Gilbert, Sylvie Garneau-Tsodikova, Matthew K Thompson
Förderung
- NIH HHS
- University of Alabama
- National Institutes of Health
Zitieren
APA
Wiltsie, V., Smith, T., Thamban Chandrika, N., Gilbert, N. C., Garneau-Tsodikova, S., & Thompson, M. K. (2026). Inhibition of Fosfomycin Resistance Protein FosA from Pseudomonas aeruginosa. ACS Infectious Diseases, 12(9), 3043-3052. https://doi.org/10.1021/acsinfecdis.6c00121
Vancouver
Wiltsie V, Smith T, Thamban Chandrika N, Gilbert NC, Garneau-Tsodikova S, Thompson MK. Inhibition of Fosfomycin Resistance Protein FosA from Pseudomonas aeruginosa. ACS Infectious Diseases. 2026;12(9):3043-3052. doi:10.1021/acsinfecdis.6c00121
BibTeX
@article{Wiltsie2026,
author = {Wiltsie, Vanessa and Smith, Tatum and Thamban Chandrika, Nishad and Gilbert, Nathaniel C and Garneau-Tsodikova, Sylvie and Thompson, Matthew K},
title = {Inhibition of Fosfomycin Resistance Protein FosA from Pseudomonas aeruginosa},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {9},
pages = {3043--3052},
doi = {10.1021/acsinfecdis.6c00121}
}
EUVIMED